Ten adult monkeys, eight on negatively reinforced (low level shock) tasks and two on positively reinforced (food reward) tasks, were injected with either 2 mg, 4 mg, or 1 mg followed by 2 mg decaborane per kg body weight, and their performance on various operant tasks was compared with baseline performance. All animals exhibited a performance decrement on at least one task, with 75% of the subjects exhibiting a decrement on the remaining tasks. In over half the cases performance changes preceded clinical symptoms.
various operant tasks was compared with baseline performance. All animals exhibited a performance decrement on at least one task, with 75% of the subjects exhibiting a decrement on the remaining tasks. In over half the cases performance changes preceded clinical symptoms.
There was no significant difference between the 2 mg and 4 mg exposures when a subject showed a decrement on negatively reinforced tasks. However, those subjects that received 1 mg followed the next day by 2 mg (positively reinforced animals) did not noticeably improve or return to baseline for a much longer period than the 2 mg and 4 mg groups (negatively reinforced).
Subjects exposed to levels of decaborane such as those employed in this research may be expected to exhibit a performance decrement or clinical symptoms during the first fifty hours, since one or the other will probably occur during that time period. Usually, the first indication will be a performance decrement on a task requiring continuous motor behavior or a series of discriminations within the first 30 hours.
Tasks of a discrete nature may, at lower exposure levels, reflect no decrement and, in these instances, there may also be a total absence of clinical symptoms. When performance decrements do take place, one may expect a return to baseline between 3 and 10 days. The boron hydrides (boranes) which, according to Rozendaal (ref 8) , were first described in 1879, have been given much attention for the past 20 years, particularly during the last decade.
With the advent of the space age, the boranes have been used extensively as high energy fuels (HEFs). The toxicology and toxicity of these compounds have been studied by numerous investigators (ref [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Their research has revealed that borane toxicity produces central nervous system symptoms in the form of headaches, depression, muscular fa'ciculations, la_ýk of awareness, and even catatonic stupors.
Differential electroencephalograms have been shown for certain brain areas via deep electrode placements (ref 2), and in human exposures marked personality changes have been observed.
Although a great deal of research on the pharmacology, toxicity, and clinical manifestations of the boranes has been accomplished, no one has studied the effects on learned behavior (performance).
Therefore, the purpose of this investigation was to evaluate animal performance following injection of decaborane. Decaborane, B H , is a white crystalline material, soluble in olive or cottonseed oil (but not in water) and is rapidly absorbed by inhalation or through the skin.
II. METHOD

A. Subjects
The subjects were 10 adult Macaque monkeys (Macaca Mulatta and Macaca Irus), weighing between 4. 32 and 7. 39 kg. All monkeys had been trained on the performance tasks to a stabilized level over a period of several months. Subjects Z2 and 23 were not trained on the auditory monitoring task.
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B. Apparatus
The apparatus was composed of two major items: a work chamber, especially designed for psychopharmacological research, and a rack of electronic relay circuitry for programing the performance tasks ( fig. 1) . The inside dimensions of the work area of the chamber were 24 by 24 by 26 inches, and the performance panel measured 13. 5 by 14 inches. The performance panel included two stimulus lights and two response levers, one set mounted on each side of an auditory stimulus-response key. The stimulus-response key contained 0. 125-inch diameter holes to permit the presentation of a tone from a speaker mounted behind it. A red lamp was mounted above the right lever as a cue for a continuous avoidance task, and a blue lamp, above the left lever, as a cue for a discrete avoidance task.
C.
Performance Schedule
The schedule was of 15 minutes duration and was comprised of three integrated tasks. At the onset of the red lamp above the right lever, the subject had to press the lever at least once every 15 seconds for the full 15 minutes. If the monkey failed to respond as often as required it received a mild shock to the soles of its feet. Since the subject diligently presses the lever to insure against shock this task has been labeled continuous avoidance (CA). Throughout the 15 -minute work period the blue lamp above the left lever was turned on at 2, 5, 8, 11, and 14 minutes and the subject was required to turn the lamp off by pressing the corresponding lever within two seconds (discrete avoidance -DA). Failure to respond within the specified time period resulted in a mild shock to the soles of the feet. The third task of the performance schedule was an auditory monitoring (AM) task, which also ran concurrently with CA and involved the presentation of a 1024 cps tone at 80 db from the speaker described in section B. Presentations of the auditory stimulus occurred at 3.5, 5, 7.5, 11, and 13.5 minutes, and the subject was required to turn the tone off by pressing the response key within 2 seconds. Failure to respond within the allotted time resulted in a mild shock to the soles of the feet. 
Procedure
The subjects were divided into two groups of four each based on level of performanre and comparable body weight. After being restrained in squeeze cages, the subjects were injected with either 2 or 4 mg decaborane per kg of body weight as indicated in table I. At 0900 subjects 4 and 9 (group I) and subjects 8 and 23 (group II) began the 15-minute performance program and continued on the hour, i.e. 1000, 1100, etc. for a total of eight sessions each day throughout the experiment. At 0930 subjects 2 and 22 (group I) and subjects 7 and 15 (group II) also began the performance program and continued on the half hour, i. e. 1030, 1130, etc for eight sessions each day throughout the experiment. Each animal served as its own control since pre-experimental task performance was sufficiently stabilized for each subject.
Two additional monkeys were injected with 1 mg decaborane per kilogram at 0855 and 0900 on the same day as the other eight monkeys, and with 2 mg per kg the following day at the same times. These two subjects were trained on positively reinforced (food pellets) discrimination tasks, primarily to evaluate decaborane effects on the hunger drive. Since the major concern in any high risk situation for humans is the ability of an individual to act on his environment in promoting safety and survival, it was considered important to compare motivational levels under both positive and negative reinforcement conditions. If an animal subject is capable of carrying out a learned task under positive reinforcement conditions but does not do so simply because his hunger drive is r diminished, then an accurate evaluation of performance changes due to sensory-motor incapacitation is'not possible. On the other hand, if motivation is strong enough (avoidance of pain), then the animal subject should make every possible effort to perform at his highest level of capability. Data on the outcome of this ancillary aspect of the experimentation are presented in the Results and DiscussionConclusions Sections.
III. RESULTS
The results can be best presented by referring to each of the subjects separately. Qualitative and quantitative subject differences preclude a meaningful group approach.
A. Group I (2 mg decaborane per kg body weight) Subject No. 2
Summary of Performance
CA performance was somewhat depressed from the very beginning, but did not drop below baseline until the 48th hour. At the 144th hour following injection, the subject evidenced a definite improvement in performance, then declined somewhat at the 151st hour. At the 170th hour the subject returned to and continued to maintain his baseline CA performance.
The compound appeared only to reduce the overall level of CA responding, and at no time throughout the 8 days of testing was this subject impaired to the point of being unable to respond. DA and AM performance were virtually unaffected during the entire experiment. Figure 2 provides a graphic presentation of the significant performance changes when compared with baseline data.
Pertinent Observations
No clinical symptoms.
Subject No. 4
Summary of Performance CA performance fell immediately below baseline following injection, but returned briefly to baseline level at the 6th and 8th hours and again at the 26th-28th hours. A significant decrement occurred simultaneously on all tasks between the 29th and 31st hours and the subject became completely impaired at the 51st hour. At the 122nd hour the subject began to perform again and evidenced a noticeable improvement on all three tasks between the 124th and 126th hours. Performance returned to and was maintained at baseline level on all tasks beginning at the 144th hour. Figure 3 provides a graphic presentation of the significant performance changes when compared with baseline data. r21.00- 
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Summary of Performance
Performance was never completely impaired and only CA performance reflected a decrement during the experiment. CA performance fell below baseline only at the 31st, 48th, 52nd and 77th hours. At the 78th hour the subject returned to and maintained baseline level performance. Figure 4 provides a graphic presentation of the significant performance changes when compared with baseline data. 28th hour. At the 30th hour performance became completely impaired and the subject did not respond again until the 96th hour. At the 96th hour the subject returned to his DA baseline performance level but at the 103rd hour became impaired once again and did not recover completely until the 120th hour. CA performance also returned to baseline level at the 120th hour, but from the 168th-240th hours performance remained slightly below baseline. After the 240th hour performance at baseline level was maintained. Figure 5 provides a graphic presentation of the significant performance changes when compared with baseline data.
Pertinent Observations
Day 1 1645 Showed a downward trend from the 3rd to the 8th hours of performance which was not at all characteristic of this subject.
Day 2 0855
Is very aggressive and hits the cage hard when approached; however, he has cut his CA lever presses down to 32 per minute from the previous low of 53 per minute.
1200
Showed a decided performance decrement on the CA variable during the 1145-1200 work session. He took 15 CA shocks and his response rate was about 25% of his lowest pre-experimental level. He beat his head against the wall and was very disturbed (first clinical signs).
1352 -Started to bite chunks of flesh and hair out of his forearms. He sits and chews these chunks as if he were in no pain whatsoever.
1400 -Continuing to bite chunks out of his arms and legs.
1402 -Removed from work situation and placed in an open wire cage for observation and then further placed in a restraint chair.
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Day 9
1315 -Seems to be "improving," then gets "worse" -he is fluctuating and is still below baseline performance.
1600 -Still below his baseline performance level and will continue work tomorrow.
Day 10 0800 -Entered his work chamber readily and looks clinically sound.
-
Will continue until his performance is considered "typical."
Day 11
1600
Is functioning at a very stable level and the experimenters are of the opinion that the subject has recovered from the effects of the decaborane.
B. Group II (4 mg decaborane per kg bodily weight)
Subject No. 7
Summary of Performance
This subject exhibited the most dramatic decrement and recovery of any of the eight subjects. Performance on all tasks fell below baseline at hour 25 and the next hour became completely impaired. On the last work session of day 6 (hour 128) the subject did not respond at all, but at the first session the next morning (hour 144) he performed at baseline level on all tasks and maintained this level throughout the day. Figure 6 provides a graphic presentation of the significant performance changes when compared with baseline data. 1600 -Has returned to his baseline level of performance (for last 8 hours work) and will no longer continue in the testing program.
Subject No. 8
Performance on CA and AM fell below baseline level at the 49th hour and DA at the 5Znd hour. The subject became completely impaired on all tasks at the 53rd hour. The subject began to attempt to respond on DA again at the 72nd hour. Between hours 76 and 144 performance on DA improved and worsened dramatically, but at the 144th hour performance returned to a stable baseline level and was maintained. Performance on CA began again at the 144th hour and from the 145th hour onward was of baseline quality. Auditory Monitoring performance was attempted infrequently between hours 72 and 144, but to little avail. Performance on AM returned to and was maintained at baseline level beginning at the 149th hour. Figure 7 provides a graphic presentation of the significant performance changes when compared with baseline data. Is confused, made one DA lever press but cannot cope with the rest of the performance program. Turned off apparatus after 12 minutes.
1500 -Has tried to perform on four occasions today but took too many shocks and program was turned off.
Day 5 0800 -Readily alerted but has tremors and prefers a huddled position. He is clinically aware but will not work.
1015 -Worked a little.
Day 6
0920 -Did not perform as well from 0900-0915 as he did from 0800-0815.
0945 -Is more easily aroused today and exhibits aggressive responses (baring of teeth and jumping at experimenters).
-
Is not responding and still greatly confused. 
Summary of Performance
Performance on CA and AM took downward trend soon after injection, with AM falling below baseline at the 5th hour and CA at the 7th hour. DA performance did not drop below baseline until the 24th hour. On day 2, at the 24th hour performance on all tasks was negligible and by the 26th hour the subject was totally impaired. On day 6 (hour 120) the subject exhibited a noticeable improvement in CA and DA performance but this was sporadic until hours 247 and 243 for CA and DA, respectively, at which time these two tasks were of baseline quality. As the subject recovered from the effects of the decaborane she exhibited escape instead of avoidance behavior to the auditory stimulus by standing on a lever. Since she could escape the shock she simply would not work on AM. Consequently, no measures were available for the recovery period. Figure 8 provides a graphic presentation of the significant performance changes when compared with baseline data.
Pertinent Observations
Day 1
-
Lying down, appears to sleep after working from 1230-1245.
-Emesis following 1430-1445 work session.
1645 -Showed a decided downward trend from the 3rd to the 8th hours of performance and this was not at all characteristic of the normal behavior for this subject.
Day 2 0845 -
Will not work, performance highly deteriorated. Clinically this subject looks fine and is alert to implied threats.
0855 -Has fixated inappropriately on the CA lever for the past 10 minutes (not pressing and releasing, just holding lever down). No ptosis observed in her and no muscular twitches or fasciculations.
0915 -Still fixated on the CA lever but is alert to implied threats. She is salivating and almost catatonic. 1200 -Very agitated. Started off session pounding CA lever, and after first DA began to try to escape.
Day 9
1125 -Biting herself and is highly restless. Behaves very similar to subject No. ZZ before he had to be restrained to keep him from injuring himself.
1315 -Is still evasive in her performance (tries to climb up to ceiling when stimuli are presented). Still below baseline performance level.
Day 10 0800 -Entered her work chamber readily and looks clinically sound. Appears to be calm enough this morning and is not trying to injure herself.
-
Will continue working until her performance is considered "typical. "
1600 -Functioning at a very stable level and the experimenters are of the opinion that she has recovered from the effects of the decaborane.
Subject No. 23
Summary of Performance
Performance was depressed following injection but CA did not fall below baseline until the 24th hour and DA the 28th hour. At the 31st hour DA performance became completely impaired followed by CA at the 49th hour. On day 5 (hours 101 to 103) the subject exhibited a noticeable improvement but it was not until day 6 (hour 122) that CA performance could be construed as "normal." DA performance did not return to baseline until the 247th hour. Figure 9 provides a graphic presentation of the significant performance changes when compared with baseline data. 1315 -Is improving and is beginning to look somewhat "normal" again.
Day 9
1315 -DA performance still below baseline.
1600 -Is still below DA baseline performance level and must continue work tomorrow.
Day 10 0800 -Entered work chamber readily and looks clinically sound.
1600 -Is within baseline performance limits.
Day 11 0800 -Decided to "run" subject one more day just to make sure that he is functioning typically.
1600
Is functioning at a very stable level and the experimenters are of the opinion that he has fully recovered from the effects of the decaborane. Table II provides a summary of the experimental results, including information on the two subjects that were positively reinforced. The initial hour of onset of clinical symptoms is reported alongside the behavioral data.
IV. DISCUSSION AND CONCLUSIONS
All animals subjected to decaborane injection did show a performance decrement on at least one task. However, two of the Group I subjects (No. 2 and No. 9) did not exhibit a significant decrement at any time on the Discrete Avoidance and Auditory Monitoring, nor did they exhibit any clinical symptoms of sickness. Further, the other two subjects from Group I (No. 4 and No. 22) exhibited performance decrements on all tasks in advance of clinical symptoms. This was also true of two of the Group IH subjects (No. 8 and No. 23), as well as the two subjects which were on the positively reinforced discrimination tasks. In only two subjects (No. 7 and No. 15, group II) did clinical symptoms precede performance decrements, and one of these (No. 15) by only one hour.
The results suggest that if a subject does show a decrement below the baseline level on a negatively reinforced task (CA, DA or AM), there will not be a significant difference between the 2 mg and 4 mg exposures as regards time of total impairment, noticeable improvement, and return to baseline performance levels. Those subjects working under positive reinforcement conditions (food reward), which received 1 mg followed by 2 mg the next day, may not show noticeable improvement or return to baseline for a much longer period when compared with the 2-mg and 4-mg groups. This seems to suggest that an accurate evaluation of an animal's ability to perform at a given time in a high risk situation may best be achieved by employing negative reinforcement (avoidance of discomfort).
The two key factors -performance changes and clinical symptoms -which may alert responsible personnel to decaborane exposure, must be examined for each of the behavioral tasks employed in this research effort. The relationship between these two factors is presented in table III.
In conclusion, following decaborane injection at the doses used in this research, one may expect 100% of the subjects to show a performance decrement in at least one essential work area, with 75% of the subjects exhibiting a decrement on the remaining tasks. In over half the exposures a change in performance will precede clinical symptoms by a distinctive time period, but in one-fifth of the exposures clinical illness will precede performance changes. In one-twelth of the exposures a performance decrement may occur but there will not be associated clinical illness. And in one-sixth of the cases there will be neither illness nor performance changes.
Personnel who are exposed to the levels of decaborane employed in this study may be expected to exhibit a performance decrement or clinical symptoms in the first 50 hours, since one or the other will probably occur during that time period. Usually, the first indication will be a performance decrement within the first 30 hours on a task requiring continuous motor behavior or a series of discriminations. Tasks of a discrete nature may, at lower exposure levels, reflect no decrement and, in these instances, there may also be a total absence of clinical symptoms. When performance decrements do take place one may expect a return to baseline between 3-10 days. 
